• Mater Dei's third-quarter 2026 earnings webcast featured CEO José Henrique Salvador and CFO and investor relations director Rafael Cordeiro.
• Net revenue rose 16.3% year over year to R$ 660 million, driven by higher average revenue from oncology and more complex procedures.
• EBITDA reached a record R$ 148.2 million, with a 22.5% margin.
• Management expects continued oncology growth in 2027 but sees no significant near-term margin expansion, prioritizing absolute earnings growth.
• Deleveraging remains the top capital allocation priority, with net debt at R$ 731 million and net debt-to-EBITDA at 1.4 times.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hospital Mater Dei SA published the original content used to generate this news brief on November 12, 2026, and is solely responsible for the information contained therein.